

Commentary

Open Access

How to engage Cofilin

Michael Bukrinsky

Address: The George Washington University, Department of Microbiology, Immunology and Tropical Medicine, Washington, DC 20037, USA

Email: Michael Bukrinsky - mtmmib@gwumc.edu

Published: 22 September 2008

Received: 10 September 2008

Retrovirology 2008, **5**:85 doi:10.1186/1742-4690-5-85

Accepted: 22 September 2008

This article is available from: <http://www.retrovirology.com/content/5/1/85>

© 2008 Bukrinsky; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In HIV-infected people, resting CD4⁺ T cells are the main reservoir of latent virus and the reason for the failure of drug therapy to cure HIV infection. Still, we do not have a complete understanding of the factors regulating HIV replication in these cells. A recent paper in *Cell* describes a new trick that the virus uses to infect resting T cells. Interaction between the viral gp120 and cellular HIV co-receptor, CXCR4, during viral entry initiates signaling that activates cofilin, the main regulator of actin polymerization. As a result of this activation, actin is depolymerized, thus destroying the natural barrier to HIV replication. I discuss implications of this study for our understanding of HIV biology and development of novel anti-HIV therapeutic approaches.

HIV accesses target cells via interaction between the viral envelope protein, gp120, and viral receptor and co-receptor, CD4 and CCR5 or CXCR4, respectively, on infected cells [1]. While interaction of gp120 with CD4, CCR5 or CXCR4 has been shown to induce intracellular signaling events [2-4], the role of this signaling in HIV replication remains controversial. Initial reports suggested that signaling from chemokine co-receptor is not essential for HIV-1 infection [5-7]. Indeed, transfection of CD4-positive CCR5-negative cells with mutant CCR5 unable to transduce signals made such cells fully susceptible to infection with R5 HIV-1 (R5 viruses infect cells expressing CD4 and CCR5, while X4 viruses infect cells with CD4 and CXCR4). However, these results were obtained using transformed T cell lines. In contrast, HIV-1 infection of activated primary CD4⁺ T cells, the main viral target in the body, appears to depend on signaling mediated by chemokine co-receptors [8-10]. The mechanism of this effect was found to involve actin-dependent re-localization of HIV receptors resulting in co-capping of CD4 and chemokine co-receptor [8,10], which stimulates HIV entry.

A recent paper by Wu and colleagues [11] analyzed the role of signaling in HIV infection of another important viral target, resting CD4⁺ T cells. These cells, which form the main reservoir of latent virus in the body [12], are relatively resistant to HIV infection, as reverse transcription and nuclear transport of the viral pre-integration complex (PIC) are very inefficient in non-activated T cells [13-15]. However, robust viral replication can be induced by activation of HIV-inoculated resting T cells, even several days after infection [14,16]. The authors used this model to demonstrate that pre-treatment of cells with pertussis toxin (PTX), which uncouples chemokine receptor from G proteins thus inhibiting signaling, greatly reduced HIV replication when cells were subsequently activated via CD3/CD28 stimulation [11]. In contrast, no such decrease was observed when cells were pre-treated with damnacanthal, which inhibits Lck, a signaling molecule coupled to CD4. Given that the HIV-1 NL4-3 virus used for infection is CXCR4-tropic, these results indicate that signaling from the CXCR4 receptor, but not from CD4, is critical for the ability of HIV to establish latent infection of non-activated T cells.

In an attempt to identify the step in viral replication controlled by CXCR4 signaling, the authors analyzed the early steps of infection, starting from fusion to integration. This analysis revealed that, while fusion and reverse transcription were not affected by PTX pre-treatment and thus not dependent on CXCR4-originating signaling, nuclear translocation of the viral DNA was inhibited [11]. Therefore, similar to T cell activation by PHA or CD3/CD28 stimulation [17], CXCR4 signaling activates nuclear translocation of the viral pre-integration complex, however, it does not activate reverse transcription, another critical event in the re-activation of latent HIV infection of resting T cells [13]. Of note, in contrast to CD3/CD28 activation, stimulation of HIV nuclear translocation by CXCR4 signaling was small (about 3-fold relative to PTX-pre-treated cells), and a real difference was observed only after cells were activated by CD3/CD28. Therefore, CXCR4 signaling appears to facilitate the movement of the HIV-1 genome towards and into the nucleus poising it for cell activation. When this signaling is blocked, the viral genome becomes supposedly localized to a compartment where it cannot

be activated, and then would undergo eventual degradation.

So what is the nature of this compartment? An intriguing observation reported by Yoder et al. is that HIV-induced CXCR4-dependent signaling triggers rapid polymerization and subsequent depolymerization of the cortical actin filaments (Fig. 1). Actin polymerization is an essential mechanism of chemotactic cell motility induced by chemokines [18], and has been documented for CXCR4-dependent T cell chemotaxis in response to SDF-1 or gp120 stimulation [19,20]. An unexpected finding by Yoder et al. is HIV-induced rapid depolymerization of polymerized actin (F-actin). When actin depolymerization was blocked by actin-stabilizing agent, jasplakinolide, HIV replication following cell activation was inhibited. This result suggests that actin depolymerization is critical for HIV replication. Previously, association of incoming HIV with F-actin was proposed to be a necessary step in formation of the reverse transcription complex and reverse transcription [21]. It now appears that this association has to be very transient, and if not disrupted within




Figure 1
A model depicting actin regulation by cofilin during HIV-1 infection of resting T cell. Interactions between the key factors involved in regulation of cortical actin are shown in the context of HIV-1 infection. HIV-induced signaling from CXCR4 activates phosphatase which dephosphorylates and activates cofilin. This leads to depolymerization of F-actin, releasing HIV-1 reverse transcription complex and promoting its translocation towards the nucleus. Steps requiring additional studies, such as involvement of CCR5 in cofilin activation, regulation of a switch between activation of cofilin kinase and phosphatase, the role of F-actin in HIV reverse transcription and nuclear translocation are marked by question marks. See text for details.

5 minutes after infection by actin depolymerization, it will prevent subsequent steps of HIV replication. It remains to be determined what happens to the viral reverse transcription complex during the first 5 minutes after entry and why this first time period is so critical for subsequent replication.

Thus, HIV-induced CXCR4 signaling depolymerization of cortical actin appears to support viral replication. A similar mechanism was previously ascribed to HIV-1 protein Nef, which can disrupt actin cytoskeleton and promote HIV replication [22,23]. Such multifaceted effort by the virus to depolymerize actin implies a critical role of this process in viral infection. A number of important questions remain to be addressed before this model can be accepted conclusively. Is the association with F-actin necessary for reverse transcription? Given the rapid depolymerization of actin in HIV-infected cells, this would seem unlikely. What is the role of F-actin in nuclear translocation of HIV pre-integration complex (PIC)? Live microscopy has shown that most viral particles in the cytoplasm are associated with microtubules and not with F-actin [24]. The majority of particles that associated with actin were found in the peripheral regions of the cytoplasm. This finding is consistent with rapid transfer of the PIC from actin to tubulin, which may be promoted by depolymerization of actin.

The key regulator of actin assembly and disassembly is cofilin, a member of the actin-depolymerizing factor (ADF) family of proteins [25]. Cofilin's association with actin promotes depolymerization of actin filaments [26]. Association of cofilin with actin is regulated by phosphorylation: cofilin phosphorylation at serine 3 by LIM kinase 1 prevents its association with actin [27], whereas dephosphorylation by phosphatases PP1 and PP2A stimulates this association and actin depolymerization [28]. Yoder et al. reported that in resting T cells, cofilin was largely phosphorylated (inactive), but was activated by dephosphorylation within minutes after HIV infection [11]. In contrast, cofilin in CD3/CD28-activated T cells or transformed T cell lines is in a permanently activated state. Interestingly, a transient increase in cofilin phosphorylation was observed immediately after HIV infection. This kinetic is consistent with a model that predicts a rapid association of the viral complex with F-actin which is required to form a functional reverse transcription complex (RTC), followed by depolymerization of F-actin, RTC relocation to microtubules, and migration toward the nucleus [29]. In support of this model, downregulation of cofilin using shRNA led to increased reverse transcription but decreased nuclear translocation [11].

In summary, the paper by Yoder et al. reveals a new factor that regulates HIV infection of resting T cells, and suggests

new approaches to anti-HIV therapeutic interventions. However, before treatments targeting F-actin could be developed as anti-HIV therapy, several critical questions remain to be addressed (see Fig. 1). Is the observed phenomenon specific for CXCR4 or is it also true for CCR5 signaling? Given that both receptors are coupled to $G_{\alpha i}$, one would expect that CCR5 signaling should also activate cofilin. And what is the state of cofilin activation in various populations of T cells, in particular non-activated memory T cells which are the main targets of HIV infection? In fact, T cells in the body exist in various states of activation, from fully quiescent to fully activated, as reflected by the expression of various activation markers [30]. It would be important to correlate the state of cellular activation with the status of cofilin activation, and ideally identify a cell surface marker indicative of cofilin activation. A number of mechanistic questions also beg for attention. How is CXCR4 signaling transduced to cofilin? How is the switch between initial inactivation (phosphorylation) and subsequent activation (dephosphorylation) of cofilin regulated? What happens to the virus during the time between the entry into a resting cell and subsequent cell activation? How does actin depolymerization stimulate nuclear translocation of the viral PIC? It appears that a new exciting field of studies has been born which will greatly advance our knowledge of HIV biology.

References

- Berger EA, Murphy PM, Farber JM: **Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.** *Annu Rev Immunol* 1999, **17**:657-700.
- Popik W, Hesselgesser JE, Pitha PM: **Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway.** *J Virol* 1998, **72**:6406-6413.
- Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, Littman DR: **Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.** *J Exp Med* 1997, **186**:1793-1798.
- Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, Venkatesan S, Farber JM, Fauci AS: **Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor.** *Nature* 1997, **389**:981-985.
- Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, Goldsmith MA, Charo IF: **Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity.** *Proc Natl Acad Sci USA* 1997, **94**:5061-5066.
- Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, Gerard NP, Sodroski J, Gerard C: **HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5.** *J Biol Chem* 1997, **272**:6854-6857.
- Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, Hoxie JA, Peiper SC, Doms RW: **Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.** *Proc Natl Acad Sci USA* 1997, **94**:6426-6431.
- Iyengar S, Hildreth JE, Schwartz DH: **Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells.** *J Virol* 1998, **72**:5251-5255.
- Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Oliva A, Ehler L, Mizell S, Jackson R, Ostrowski M, Hoxie J, Offord R, Fauci AS: **CC-chemokines enhance the replication of T-**

- tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction.** *Proc Natl Acad Sci USA* 1998, **95**:11880-11885.
10. Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M: **The B-Oligomer of Pertussis Toxin Deactivates CC Chemokine Receptor 5 and Blocks Entry of M-tropic HIV-1 Strains.** *J Exp Med* 1999, **190**:597-606.
 11. Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, Stephany DA, Cooper JN, Marsh JW, Wu Y: **HIV Envelope-CXCR4 Signaling Activates Cofilin to Overcome Cortical Actin Restriction in Resting CD4 T Cells.** *Cell* 2008, **134**:782-792.
 12. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: **Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.** *Nat Med* 1999, **5**:512-517.
 13. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: **HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.** *Cell* 1990, **61**:213-222.
 14. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M: **Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.** *Science* 1991, **254**:423-427.
 15. Fassati A: **HIV infection of non-dividing cells: a divisive problem.** *Retrovirology* 2006, **3**:74.
 16. Wu Y, Marsh JW: **Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.** *Science* 2001, **293**:1503-1506.
 17. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M: **Active nuclear import of human immunodeficiency virus type I preintegration complexes.** *Proc Natl Acad Sci USA* 1992, **89**:6580-6584.
 18. Howard TH, Meyer WH: **Chemotactic peptide modulation of actin assembly and locomotion in neutrophils.** *J Cell Biol* 1984, **98**:1265-1271.
 19. Sotsios Y, Whittaker GC, Westwick J, Ward SG: **The CXC Chemokine Stromal Cell-Derived Factor Activates a Gi-Coupled Phosphoinositide 3-Kinase in T Lymphocytes.** *J Immunol* 1999, **163**:5954-5963.
 20. Balabanian K, Harriague J, Decrion C, Lagane B, Shorte S, Baleux F, Virelizier JL, Renzana-Seisdedos F, Chakrabarti LA: **CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes.** *J Immunol* 2004, **173**:7150-7160.
 21. Bukrinskaya A, Brichacek B, Mann A, Stevenson M: **Establishment of a functional human immunodeficiency virus type I (HIV-1) reverse transcription complex involves the cytoskeleton.** *J Exp Med* 1998, **188**:2113-2125.
 22. Campbell EM, Nunez R, Hope TJ: **Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type I infectivity.** *J Virol* 2004, **78**:5745-5755.
 23. Lu TC, He JC, Wang ZH, Feng X, Fukumi-Tominaga T, Chen N, Xu J, Iyengar R, Klotman PE: **HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein.** *J Biol Chem* 2008, **283**:8173-8182.
 24. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Eberman M, Hope TJ: **Visualization of the intracellular behavior of HIV in living cells.** *J Cell Biol* 2002, **159**:441-452.
 25. Bamberg JR, Wiggan OP: **ADF/cofilin and actin dynamics in disease.** *Trends Cell Biol* 2002, **12**:598-605.
 26. Lappalainen P, Drubin DG: **Cofilin promotes rapid actin filament turnover in vivo.** *Nature* 1997, **388**:78-82.
 27. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P: **Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase.** *Nature* 1998, **393**:805-809.
 28. Ambach A, Saunus J, Konstantin M, Wesselborg S, Meuer SC, Samstag Y: **The serine phosphatases PPI and PP2A associate with and activate the actin-binding protein cofilin in human T lymphocytes.** *Eur J Immunol* 2000, **30**:3422-3431.
 29. Iordanskiy S, Berro R, Altieri M, Kashanchi F, Bukrinsky M: **Intracytoplasmic maturation of the human immunodeficiency virus type I reverse transcription complexes determines their capacity to integrate into chromatin.** *Retrovirology* 2006, **3**:4.
 30. McKinsty KK, Strutt TM, Swain SL: **The effector to memory transition of CD4 T cells.** *Immunol Res* 2008, **40**:114-127.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

